

2022 -- S 2612 SUBSTITUTE A

LC005031/SUB A/2

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2022

A N A C T

RELATING TO STATE AFFAIRS AND GOVERNMENT -- CORRECTIONS DEPARTMENT

Introduced By: Senators Kallman, Miller, DiMario, McCaffrey, DiPalma, Murray,
Archambault, and Bell

Date Introduced: March 10, 2022

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Chapter 42-56 of the General Laws entitled "Corrections Department" is
2 hereby amended by adding thereto the following section:

3 **42-56-43. Medication for opioid use disorder.**

4 (a) For purposes of this section, "medication for opioid use disorder" means treatment of
5 the medical diagnosis, "opioid use disorder" with medications requiring a prescription or order from
6 an authorized prescribing professional.

7 (b) The department shall establish a program to be administered at the adult correctional
8 institutions for the purpose of employing medication assisted treatment for any persons imprisoned
9 who are undergoing treatment for an opioid use disorder. Such program shall include all forms of
10 medication for opioid use disorder approved for the treatment of an opioid use disorder by the
11 federal Food and Drug Administration, and shall apply for the duration of the person's incarceration
12 and provide an individualized treatment plan for each participant.

13 (c) Within twenty-four (24) hours after admission, each inmate shall be screened for an
14 opioid use disorder as part of an ongoing opioid use screening and assessment process.

15 (d) After a medical screening, persons who are determined to suffer from an opioid use
16 disorder for which FDA-approved addiction medications exist shall be offered placement in the
17 medication for opioid use disorder program. Placement in the program shall be voluntary. Each
18 participant shall work with an authorized specialist to determine an individualized treatment plan,
19 including an appropriate level of counseling. Decisions regarding type, dosage, or duration of any

1 medication regimen shall be made by a qualified and licensed health care professional who is
2 authorized to administer such medication.

3 (e) An eligible inmate may enter into the program at any time during his or her
4 incarceration. An inmate who is taking medication for an opioid use disorder pursuant to a valid
5 prescription shall be entitled to continue using and receiving that medication pending a medical
6 evaluation.

7 (f) No person shall be denied participation in the program on the basis of a positive drug
8 screening upon entering custody or upon intake into the program; nor shall any person receive a
9 disciplinary infraction for such positive drug screening. No person shall be removed from, or denied
10 participation in, the program on the basis of having received any disciplinary infraction either
11 before entry into, or during participation in, the program.

12 (g) The program shall include a re-entry strategy for individuals who have participated in
13 medication for opioid use disorder. The strategy shall include, but not be limited to:

14 (1) Providing each participant with information on available treatment facilities in their
15 area, information on available housing and employment resources, and any other information that
16 will assist the individual in continued recovery once released;

17 (2) Sharing with parole officers accurate information regarding the inmate's participation
18 in medication for opioid use disorder to ensure that their medication is not deemed illicit or illegal.

19 (h) If a licensed practitioner makes a clinical judgment to discontinue a medication for
20 opioid use disorder the patient had been using prior to incarceration, the practitioner shall cause the
21 reason for the discontinuance to be entered into the patient's medical record, specifically stating
22 the reason for the discontinuance. The inmate shall be provided, both orally and in writing, with a
23 specific explanation of the decision to discontinue the medication and with notice of the right to
24 have his or her community-based prescriber notified of the decision. If the patient provides signed
25 authorization, the department shall notify the community-based prescriber in writing of the decision
26 to discontinue the medication.

27 (i) The department shall submit, within one year of the effective date of this section and
28 annually thereafter, a report to the governor and the general assembly on the effectiveness of the
29 program established pursuant to this section. Such reports shall include an analysis of the impact
30 of such program on the participants, including factors such as disciplinary incidents, reentry rates,
31 among other related relevant factors. The reports shall also include the impact on institutional safety
32 and performance and any recommendations for additional legislative enactments that may be
33 needed or required to improve or enhance the program as determined to be appropriate by the
34 department.

1 SECTION 2. This act shall take effect on January 1, 2023.

=====
LC005031/SUB A/2
=====

EXPLANATION
BY THE LEGISLATIVE COUNCIL
OF
A N A C T
RELATING TO STATE AFFAIRS AND GOVERNMENT -- CORRECTIONS DEPARTMENT

1 This act would establish a program within the adult correctional institutions to permit
2 medication for opioid use disorder approved by the FDA for the treatment of an opioid use disorder
3 to any individual incarcerated. Each inmate would be screened for opioid use disorder within
4 twenty-four (24) hours of incarceration and if determined to be suffering from an opioid use
5 disorder would be offered placement in the medication for opioid use disorder program.

6 This act would take effect on January 1, 2023.

=====
LC005031/SUB A/2
=====